Scholarlink

Objective <p>Examine neonatologists’ perspectives on disclosing rapid genomic sequencing (rGS) results, including the barriers and facilitators they perceive.</p> Study design <p>Neonatologists from 10 NICUs participating in the Virtual Genome Center (VIGOR) study were surveyed after each rGS disclosure and interviewed regarding their experience after 2 or more disclosures. Quantitative results were compared by result type, and qualitative results were iteratively coded for themes.</p> Results <p>93% of neonatologists felt comfortable disclosing rGS results regardless of result type. Neonatologists utilized multiple resources to prepare for disclosures, including the VIGOR Clinical Interpretive Report, medical literature, and local genetics experts. They preferred to have a geneticist present during disclosure when possible. Neonatologists were motivated to participate in disclosures to help families and leverage existing trust.</p> Conclusion <p>Neonatologists are important to the rGS disclosure experience, but a joint effort with genetics experts may be the ideal model to successfully expand access.</p> Trial Registration Number <p><a href="https://bmjopen.bmj.com/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT05205356&amp;atom=%2Fbmjopen%2F14%2F2%2Fe080529.atom">NCT05205356/clinicaltrials.gov</a>.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Understanding perspectives of safety-net NICU neonatologists disclosing genomic sequencing results: a mixed methods approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月5日

查看全文
  • Sonia Hills,
  • Meghan Werner,
  • Jessica Douglas,
  • Alissa M. D’Gama,
  • Monica H. Wojcik,
  • Vanessa Young,
  • Timothy W. Yu,
  • Pankaj B. Agrawal,
  • Margaret G. Parker

摘要

Objective

Examine neonatologists’ perspectives on disclosing rapid genomic sequencing (rGS) results, including the barriers and facilitators they perceive.

Study design

Neonatologists from 10 NICUs participating in the Virtual Genome Center (VIGOR) study were surveyed after each rGS disclosure and interviewed regarding their experience after 2 or more disclosures. Quantitative results were compared by result type, and qualitative results were iteratively coded for themes.

Results

93% of neonatologists felt comfortable disclosing rGS results regardless of result type. Neonatologists utilized multiple resources to prepare for disclosures, including the VIGOR Clinical Interpretive Report, medical literature, and local genetics experts. They preferred to have a geneticist present during disclosure when possible. Neonatologists were motivated to participate in disclosures to help families and leverage existing trust.

Conclusion

Neonatologists are important to the rGS disclosure experience, but a joint effort with genetics experts may be the ideal model to successfully expand access.

Trial Registration Number

NCT05205356/clinicaltrials.gov.